Hodgkin lymphoma
Objective: Evaluate the effectiveness of brentuximab vedotin plus bendamustine regimen in treatment of relapsed and refractory (RR) Hodgkin lymphoma (HL) patients at Cho Ray hospital.
Objective : Evaluate the effectiveness of brentuximab vedotin plus bendamustine regimen in treatment of relapsed and refractory ( RR ) Hodgkin lymphoma ( HL ) patients at Cho Ray hospital .